Validation of rapid and simple LC-MS/MS method for determination of voriconazole in rat plasma

被引:26
作者
Araujo, Bx
Conrado, D. J.
Palma, E. C.
Costa, Teresa Dalla
机构
[1] Univ Fed Rio Grande do Sul, Fac Farm, Programa Posgrad Ciencias Farmaceut, BR-90610000 Porto Alegre, RS, Brazil
[2] Univ Fed Rio Grande do Sul, Fac Farm, Ctr Bioanalit Medicamentos, BR-90046900 Porto Alegre, RS, Brazil
关键词
voriconazole; LC-MS/MS; pharmacokinetics; biologic fluid; validation;
D O I
10.1016/j.jpba.2007.03.026
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A rapid, simple and sensitive LC-MS/MS analytical method was developed and validated for the determination of voriconazole (VRC) in rat plasma, using ketoconazole as internal standard (IS). Analysis was performed on a Shimadzue HPLC system using a Shimadzu((R)) C18 column and isocratic elution with acetonitrile-water-formic acid (60:40:0.05, v/v/v), at a flow of 1.0mL/min (split ratio 1:5), and a mass spectrometer Micromasso, equiped with a double quadrupole and an electrospray ionization interface, operated in a positive mode. Plasma samples were deproteinized with methanol (1:2) and 30 mu L of the supernatant was injected into the system. The retention times of VRC and IS were approximately 3.3 and 2.7 min, respectively. Calibration curves in spiked plasma were linear over the concentration range of 50-2500 ng/mL with determination coefficient > 0.98. The lower limit of quantification was 50 ng/mL. The accuracy of the method was within 5%. Intra- and inter-day relative standard deviations were less or equal to 12.5 and 7.7%, respectively. The applicability of the LC-MS-MS method for pharmacokinetic studies was tested using plasma samples obtained after intravenous administration of VRC to male Wistar rats. The reported method provided the necessary sensitivity, linearity, precision, accuracy, and specificity to allow the determination of VRC in pre-clinical pharmacokinetic studies. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:985 / 990
页数:6
相关论文
共 20 条
[1]   In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model [J].
Andes, D ;
Marchillo, K ;
Stamstad, T ;
Conklin, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) :3165-3169
[2]   In vivo pharmacodynamics of a new triazole, ravulconazole, in a murine candidiasis model [J].
Andes, D ;
Marchillo, K ;
Stamstad, T ;
Conklin, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1193-1199
[3]   Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis [J].
Andes, D ;
Marchillo, K ;
Conklin, R ;
Krishna, G ;
Ezzet, F ;
Cacciapuoti, A ;
Loebenberg, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :137-142
[4]  
[Anonymous], 2001, BIOAN METH VAL GUID
[5]   Fast, fully automated analysis of voriconazole from serum by LC-LC-ESI-MS-MS with parallel column-switching technique [J].
Egle, H ;
Trittler, R ;
König, A ;
Kümmerer, K .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 814 (02) :361-367
[6]   In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) :198-202
[7]   A rapid HPLC assay for voriconazole in human plasma [J].
Gage, R ;
Stopher, DA .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 17 (08) :1449-1453
[8]   Use of voriconazole in treatment of Scedosporium apiospermum infection:: Case report [J].
Girmenia, C ;
Luzi, G ;
Monaco, M ;
Martino, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (05) :1436-1438
[9]   Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry [J].
Keevil, BG ;
Newman, S ;
Lockhart, S ;
Howard, SJ ;
Moore, CB ;
Denning, DW .
THERAPEUTIC DRUG MONITORING, 2004, 26 (06) :650-657
[10]   Clinical pharmacokinetics of voriconazole [J].
Levque, Dominique ;
Nivoix, Yasmine ;
Jehl, Francois ;
Herbrecht, Raoul .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2006, 27 (04) :274-284